tradmap

ABOS Earnings Acumen Pharmaceuticals, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$5 -$3 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$121M -$61M $0 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-172% -66% 39% 0% 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$2 -$1 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$41M -$20M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-57% -29% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–21 of 21
Q2 20262026-06-30-0.792026-08-1210-Q
Q1 20262026-03-31-0.332026-05-1210-Q
FY 20252025-12-31-2.002026-03-2610-K
Q3 20252025-09-30-1.592025-11-1210-Q
Q2 20262025-06-30-1.152026-08-1210-Q
Q1 20262025-03-31-0.482026-05-1210-Q
FY 20252024-12-31-1.712026-03-2610-K
Q3 20252024-09-30-1.092025-11-1210-Q
Q2 20252024-06-30-0.592025-08-1210-Q
Q1 20252024-03-31-0.252025-05-1310-Q
FY 20242023-12-31-1.082025-03-2710-K
Q3 20242023-09-30-0.792024-11-1210-Q
Q2 20242023-06-30-0.562024-08-1310-Q
Q1 20242023-03-31-0.282024-05-1410-Q
FY 20232022-12-31-1.062024-03-2610-K
Q3 20232022-09-30-0.742023-11-1310-Q
Q2 20232022-06-30-0.482023-08-0810-Q
Q1 20232022-03-31-0.232023-05-0910-Q
FY 20222021-12-31-5.022023-03-2710-K
Q3 20222021-09-30-7.002022-11-1410-Q
Q2 20222021-06-30-207.522022-08-1510-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.